CSWS, Landau-Kleffner & Sleep-Related Epilepsies
Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS), also known as electrical status epilepticus during slow-wave sleep (ESES), and Landau-Kleffner syndrome (LKS, acquired epileptic aphasia) represent a spectrum of sleep-related epileptic encephalopathies in which near-continuous epileptiform activity during non-rapid eye movement (NREM) sleep causes progressive cognitive and behavioral regression. The ILAE 2022 classification unifies these conditions under the broader category of developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep (DEE-SWAS), recognizing that they share the core pathophysiologic mechanism of sleep-potentiated epileptiform discharges disrupting normal sleep-dependent cognitive consolidation. Sleep-related hypermotor epilepsy (SHE), formerly nocturnal frontal lobe epilepsy, represents a distinct syndrome of clusters of brief hyperkinetic seizures arising from sleep, often with autosomal dominant inheritance. Together, these conditions highlight the critical relationship between sleep, epileptiform activity, and cognitive function in the developing brain.
Bottom Line
- CSWS/ESES: Defined by a spike-wave index (SWI) ≥50% during NREM sleep (historically ≥85% for "classic" CSWS); causes global cognitive regression including language, executive function, behavior, and motor skills; the EEG pattern, not seizure frequency, drives the encephalopathy
- Landau-Kleffner syndrome (LKS): Selective acquired epileptic aphasia in a previously normally developing child; auditory verbal agnosia (inability to comprehend spoken language) is the hallmark; spike-wave activation in sleep is centered over temporal regions; seizures may be infrequent or absent
- DEE-SWAS (ILAE 2022 term): Umbrella designation encompassing CSWS, LKS, and related conditions; emphasizes that the epileptiform EEG pattern during sleep is the primary driver of cognitive dysfunction
- Treatment: High-dose benzodiazepines (diazepam, clobazam), corticosteroids (oral prednisolone, IV methylprednisolone, ACTH), and select antiseizure medications (valproate, ethosuximide, levetiracetam); traditional ASMs alone are often inadequate
- Sleep-related hypermotor epilepsy (SHE): Clusters of brief, stereotyped hyperkinetic seizures from NREM sleep; genetic causes include CHRNA4, CHRNB2, CHRNA2, KCNT1, and DEPDC5; often responsive to low-dose carbamazepine
- Prognosis: CSWS/LKS seizures typically resolve by adolescence, but cognitive deficits may be permanent if treatment is delayed; earlier and more aggressive treatment is associated with better neurodevelopmental outcomes
CSWS / Electrical Status Epilepticus During Sleep (ESES)
Definition and Terminology
CSWS was first described in 1971 by Patry, Lyagoubi, and Tassinari as a pattern of continuous, bilateral, or sometimes focal spike-and-wave discharges occupying a significant proportion of NREM sleep. The terminology has evolved:
- ESES (electrical status epilepticus during sleep): Describes the EEG pattern itself—near-continuous spike-and-wave activity during NREM sleep
- CSWS: Refers to the clinical syndrome—ESES pattern plus cognitive/behavioral regression and clinical seizures
- DEE-SWAS: The ILAE 2022 terminology, encompassing both CSWS and LKS under a unified framework
- Spike-wave index (SWI): The proportion of NREM sleep occupied by spike-and-wave discharges; traditionally, SWI ≥85% defined CSWS, but it is now recognized that SWI ≥50% can cause significant cognitive impairment; the threshold is more clinically meaningful when correlated with cognitive function rather than treated as an absolute cutoff
Epidemiology and Etiology
CSWS is rare, accounting for approximately 0.5–1% of childhood epilepsies. The typical age of onset for the ESES pattern is 2–12 years, with a peak at 4–8 years. Etiologies include:
| Etiologic Category | Examples | Notes |
|---|---|---|
| Structural | Perinatal thalamic injury; early thalamotomy; polymicrogyria; focal cortical dysplasia; porencephaly; hydrocephalus (shunted) | Thalamic lesions are strongly associated with ESES/CSWS, consistent with the role of the thalamus in generating and propagating sleep-related oscillations |
| Genetic | GRIN2A (most well-established); KCNQ2; CNKSR2; SLC6A1; copy number variants (15q11.2-13.1 duplication) | GRIN2A variants are found in up to 10–20% of cases; the same gene is associated with the spectrum from SeLECTS to LKS to CSWS |
| Evolution from other epilepsies | Atypical evolution of SeLECTS (rare); progression from other focal epilepsies | A small subset of children with SeLECTS develop ESES and cognitive regression, representing the severe end of the rolandic epilepsy spectrum |
| Unknown | No identifiable structural, genetic, or metabolic cause | Substantial proportion; may represent undiscovered genetic causes |
Clinical Features
The hallmark of CSWS is progressive cognitive and behavioral deterioration temporally associated with the emergence of the ESES pattern on EEG:
- Cognitive regression: Global deterioration affecting multiple domains—language, executive function, visuospatial skills, memory, and attention; may present as declining school performance, behavioral changes, or loss of previously acquired skills
- Behavioral disturbances: Hyperactivity, aggression, impulsivity, emotional lability; may be the presenting complaint before cognitive regression is recognized
- Motor regression: In some patients, motor function is affected, including ataxia, dyspraxia, or even unilateral motor deficits (epileptic negative myoclonus)
- Seizures: Variable; may include focal motor seizures, atypical absences, atonic seizures (drop attacks), or generalized tonic-clonic seizures; importantly, seizures may be infrequent or even absent—the cognitive regression is primarily driven by the ESES pattern rather than clinical seizures
EEG Features
| EEG Feature | Description |
|---|---|
| NREM sleep pattern | Near-continuous bilateral (sometimes unilateral or focal) spike-and-wave discharges, often maximal frontal or diffuse; SWI ≥50% (classically ≥85%); typically 1.5–3 Hz |
| REM sleep | Marked attenuation or disappearance of the spike-and-wave activity; this NREM-REM discrepancy is a key diagnostic feature |
| Waking EEG | Focal or multifocal epileptiform discharges; may show background slowing; normal or mildly abnormal in early stages |
| Sleep architecture | Disrupted sleep stages; loss of normal sleep spindles and K-complexes; reduced REM sleep proportion in severe cases |
| Monitoring requirements | Overnight or prolonged EEG with adequate NREM sleep recording is ESSENTIAL; a routine 30-minute EEG may miss the pattern entirely |
When to Suspect CSWS/ESES
- Any child with epilepsy (especially SeLECTS or other focal epilepsy) who develops cognitive or behavioral regression—obtain an overnight EEG
- A child with known epilepsy whose seizures are well-controlled but who is experiencing declining school performance, behavioral changes, or language regression
- Worsening EEG with increasing spike-wave activity during sleep, even without clinical seizure worsening
- Routine awake-only EEGs are INSUFFICIENT for detecting ESES; if the clinical picture is suspicious, an overnight EEG is mandatory
- Earlier diagnosis and treatment of the ESES pattern is associated with better cognitive outcomes; delays in recognition are common and detrimental
Landau-Kleffner Syndrome (Acquired Epileptic Aphasia)
Clinical Features
Landau-Kleffner syndrome (LKS), first described in 1957, is a rare but distinctive epileptic encephalopathy characterized by acquired aphasia in a previously normally developing child:
- Auditory verbal agnosia: The hallmark feature; loss of the ability to comprehend spoken language despite preserved hearing; the child may appear deaf; results from disruption of temporal lobe language networks by epileptiform activity
- Language regression: Receptive language loss precedes or accompanies expressive language loss; may progress from subtle comprehension difficulties to complete loss of verbal communication over weeks to months
- Age of onset: Typically 3–8 years, after normal language development has been established; distinguishes LKS from congenital language disorders
- Seizures: Present in approximately 70–80% of patients; usually infrequent and easily controlled; seizure types include focal motor, atypical absence, and generalized tonic-clonic; seizure severity does NOT correlate with language regression severity
- Behavioral changes: Hyperactivity, aggression, and attention difficulties are common; may be misdiagnosed as autism or behavioral disorder before the language regression is fully recognized
EEG Features
- Interictal: Spike-and-wave discharges centered over temporal regions (particularly perisylvian cortex), often bilateral; may be unilateral initially
- NREM sleep: Marked activation with continuous or near-continuous spike-and-wave activity (ESES pattern), often with temporal predominance; SWI is typically elevated but may not reach the ≥85% threshold seen in CSWS
- Magnetoencephalography (MEG): Can help localize the epileptiform source to the perisylvian region, which is useful for surgical planning in refractory cases
Distinction Between LKS and CSWS
| Feature | Landau-Kleffner Syndrome | CSWS (Non-LKS) |
|---|---|---|
| Cognitive deficit | Selective: acquired aphasia (auditory verbal agnosia) | Global: multiple cognitive domains affected |
| EEG topography | Temporal/perisylvian predominance | Diffuse or frontal predominance |
| Motor involvement | Uncommon | May include ataxia, dyspraxia, motor regression |
| Seizure frequency | Often infrequent or absent | More frequent; multiple seizure types |
| Age of onset | 3–8 years (after language acquisition) | 2–12 years (variable) |
| Recovery | Variable; partial language recovery in many; complete recovery less common | Variable; depends on etiology, SWI duration, and treatment timing |
Treatment of CSWS and LKS
Treatment Goals
The primary treatment goal in CSWS/LKS is resolution of the ESES pattern and prevention or reversal of cognitive regression. Seizure control alone is insufficient—the epileptiform activity during sleep must be addressed directly. Earlier treatment is associated with better outcomes.
Pharmacotherapy
| Treatment | Regimen | Evidence/Efficacy | Key Notes |
|---|---|---|---|
| High-dose oral diazepam | 0.5–1.0 mg/kg at bedtime × 3–4 weeks, then taper | Rapid normalization of the ESES pattern in many patients; may produce dramatic cognitive improvement within days to weeks | Sedation; tolerance with prolonged use; relapse common upon discontinuation; often used as initial "pulse" therapy |
| Clobazam | 0.5–1.0 mg/kg/day divided twice daily | Effective for reducing SWI; better tolerated for long-term use than diazepam | Sedation, drooling; tolerance may develop; often used as maintenance after initial diazepam pulse |
| Corticosteroids (oral prednisolone) | 1–2 mg/kg/day × 1–3 months, then slow taper | Effective in many patients; may resolve ESES and improve cognition; multicenter studies show superiority over ASMs alone | Weight gain, mood changes, immunosuppression, growth effects; relapse upon tapering is common; may require prolonged courses |
| IV methylprednisolone pulses | 20 mg/kg/day × 3 days, repeated monthly × 3–6 cycles | Effective in steroid-responsive cases; may achieve more sustained improvement than oral steroids alone | Requires IV access; typically given as inpatient; followed by oral prednisolone taper |
| ACTH | Various regimens (similar to infantile spasms protocols) | Effective in some refractory cases; limited comparative data | Same monitoring requirements and side effects as in infantile spasms treatment |
| IVIg | 2 g/kg over 2–5 days; may repeat monthly | Some case series report benefit; evidence is limited | Generally well tolerated; expensive; headache, infusion reactions |
| Valproate | Standard dosing | May reduce SWI as adjunctive therapy; broad-spectrum | More effective as combination therapy than monotherapy for ESES |
| Ethosuximide | Standard dosing (20–30 mg/kg/day) | Effective in some patients, particularly for spike-wave discharges; may reduce SWI | Useful add-on; does not protect against tonic-clonic seizures |
| Levetiracetam | Standard dosing | May be helpful as adjunctive therapy; limited specific evidence for ESES | Behavioral side effects (irritability); generally well tolerated otherwise |
Treatment Algorithm for CSWS/ESES
- Step 1: High-dose benzodiazepine pulse (diazepam at bedtime × 3–4 weeks) with concurrent optimization of ASM therapy; repeat EEG to assess SWI response
- Step 2: If benzodiazepine pulse is insufficient, initiate corticosteroids (oral prednisolone or IV methylprednisolone pulses); plan for a slow taper over months
- Step 3: For refractory cases, consider ACTH, IVIg, ketogenic diet, or immunotherapy (particularly if an immune-mediated etiology is suspected)
- Step 4: Epilepsy surgery evaluation in patients with focal structural lesions (e.g., perisylvian polymicrogyria, focal cortical dysplasia); multiple subpial transections may be considered for LKS refractory to medical therapy
- Throughout all steps, monitor cognitive function with serial neuropsychological assessments and adjust treatment aggressiveness based on both EEG and cognitive trajectory
Surgical Options
- Multiple subpial transections (MSTs): A surgical technique that disrupts horizontal cortical connections while preserving vertical columnar function; used in LKS to interrupt the epileptiform propagation in the perisylvian cortex without causing additional language deficits; evidence is limited but some patients show language improvement
- Resective surgery: For patients with identifiable focal structural lesions (focal cortical dysplasia, perisylvian malformations) contributing to the ESES pattern; can be highly effective
- Corpus callosotomy: Rarely considered; may reduce bilateral spike-wave propagation in highly refractory cases
Sleep-Related Hypermotor Epilepsy (SHE)
Overview
Sleep-related hypermotor epilepsy (SHE), formerly known as nocturnal frontal lobe epilepsy (NFLE), is a focal epilepsy syndrome characterized by clusters of brief, stereotyped, hyperkinetic seizures arising from NREM sleep. The ILAE renamed this syndrome to reflect that (1) the seizures are not exclusively nocturnal (they arise from any sleep period) and (2) the seizure onset zone may be extrafrontal in some cases.
Clinical Features
- Seizure semiology: Brief (typically <2 minutes), stereotyped episodes of hyperkinetic movements—thrashing, pedaling, kicking, rocking, or asymmetric tonic posturing; may include vocalizations (grunting, screaming); consciousness may be partially preserved
- Clustering: Multiple seizures per night, often 5–20 or more, typically during NREM stages N2 and N3
- Age of onset: Variable; most commonly in childhood or adolescence, but may present in adulthood
- Daytime seizures: May occur during daytime naps but are uncommon during wakefulness
- Misdiagnosis: Frequently misdiagnosed as parasomnias (night terrors, sleepwalking), psychiatric disorders, or nonepileptic events; the stereotyped nature and high frequency of events are key distinguishing features
Genetics of SHE
| Gene | Protein | Inheritance | Key Features |
|---|---|---|---|
| CHRNA4 | Nicotinic ACh receptor α4 subunit | Autosomal dominant | First gene identified in familial SHE; variable penetrance (~70%); seizures typically respond to low-dose carbamazepine |
| CHRNB2 | Nicotinic ACh receptor β2 subunit | Autosomal dominant | Similar phenotype to CHRNA4; less common |
| CHRNA2 | Nicotinic ACh receptor α2 subunit | Autosomal dominant | Rare; associated with a broader phenotype including intellectual disability in some families |
| KCNT1 | Sodium-activated potassium channel | Autosomal dominant | Gain-of-function variants; associated with more severe SHE phenotype with intellectual disability and psychiatric comorbidities; may also cause epilepsy of infancy with migrating focal seizures |
| DEPDC5 | GATOR1 complex component (mTOR pathway regulator) | Autosomal dominant | Most common genetic cause of familial focal epilepsy; may present as SHE, familial focal epilepsy with variable foci, or focal epilepsy with focal cortical dysplasia; variable penetrance |
| NPRL2, NPRL3 | GATOR1 complex components | Autosomal dominant | Similar to DEPDC5; associated with focal cortical dysplasia and focal epilepsy |
Diagnosis and Treatment of SHE
- Diagnosis: Video-EEG monitoring with a full sleep recording is essential; interictal and ictal EEG may be normal or show only movement artifact (frontal seizures are often difficult to capture on scalp EEG); the clinical history of stereotyped, clustered, hyperkinetic events from sleep is often more diagnostic than the EEG
- Treatment: Low-dose carbamazepine (200–600 mg/day) or oxcarbazepine is often highly effective, particularly in nicotinic receptor-related SHE; other options include lacosamide, perampanel, and topiramate
- KCNT1-related SHE: Often drug-resistant to standard therapies; quinidine (a potassium channel blocker) has been tried as a targeted therapy with mixed results; seizures may be refractory to multiple medications
- Surgery: May be an option for patients with MRI-visible focal lesions (focal cortical dysplasia) or stereo-EEG-confirmed focal onset
Prognosis and Neurodevelopmental Outcomes
| Condition | Seizure Outcome | Cognitive Outcome | Key Prognostic Factors |
|---|---|---|---|
| CSWS | Seizures and ESES pattern typically resolve by mid-adolescence (spontaneously or with treatment) | Variable; some recovery of cognitive function is possible, but permanent deficits are common, especially with delayed treatment; IQ loss of 20–50 points reported in series | Earlier treatment; shorter duration of ESES; lower SWI at treatment initiation; absence of structural etiology; rapid response to therapy |
| LKS | Seizures resolve by adolescence in most patients | Partial language recovery is common; complete recovery is less frequent; receptive language may remain more impaired than expressive; long-term educational support usually needed | Earlier onset may paradoxically have better outcomes (more brain plasticity); shorter interval between language regression and treatment initiation |
| SHE | Chronic; seizures persist lifelong in many patients but often well-controlled with medication | Normal cognition in most nicotinic receptor-related SHE; cognitive impairment in KCNT1-related SHE | Genetic subtype; presence of structural lesion; response to carbamazepine |
Key Clinical Pearls
- Any child with epilepsy who develops cognitive or language regression should undergo an overnight EEG to evaluate for ESES/CSWS; a routine awake EEG is insufficient
- In LKS, the language regression may precede the onset of clinical seizures; a child presenting with acquired aphasia should always have an overnight EEG even if no seizures have been observed
- Treatment of CSWS/LKS should target the EEG pattern (ESES), not just clinical seizures; aggressive immunotherapy (steroids, ACTH) is often needed beyond conventional ASMs
- For SHE, the key to diagnosis is recognizing the stereotyped, clustered nature of nocturnal events; video of the episodes is invaluable; a trial of low-dose carbamazepine may be both diagnostic and therapeutic
- GRIN2A genetic testing should be considered in children with the SeLECTS-LKS-CSWS spectrum, as it may inform prognosis and treatment decisions
- Neurodevelopmental and educational support is critical for all children with CSWS/LKS, even after seizure remission, as cognitive deficits may persist
References
- Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1398–1442.
- Tassinari CA, Rubboli G, Volpi L, et al. Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including the acquired aphasia. Clin Neurophysiol 2000;111(Suppl 2):S94–S102.
- van den Munckhof B, de Vries EE, Braun KPJ, et al. Treatment of electrical status epilepticus in sleep: a pooled analysis of 575 cases. Epilepsia 2015;56(11):1738–1746.
- van den Munckhof B, Alderweireld C, Davelaar S, et al. Treatment of electrical status epilepticus in sleep: clinical and EEG characteristics and response to 147 treatments in 47 patients. Eur J Paediatr Neurol 2018;22(1):64–71.
- Landau WM, Kleffner FR. Syndrome of acquired aphasia with convulsive disorder in children. Neurology 1957;7(8):523–530.
- Lesca G, Rudolf G, Bruneau N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 2013;45(9):1061–1066.
- Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1443–1474.
- Tinuper P, Bisulli F, Cross JH, et al. Definition and diagnostic criteria of sleep-related hypermotor epilepsy. Neurology 2016;86(19):1834–1842.
- Nobili L, Proserpio P, Combi R, et al. Nocturnal frontal lobe epilepsy. Curr Neurol Neurosci Rep 2014;14(2):424.
- Heron SE, Smith KR, Bahlo M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 2012;44(11):1188–1190.
- Dibbens LM, de Vries B, Dober S, et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet 2013;45(5):546–551.
- Seri S, Cerquiglini A, Pisani F. Spike-induced interference in auditory sensory processing in Landau-Kleffner syndrome. Electroencephalogr Clin Neurophysiol 1998;108(5):506–510.